Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the... see more

TSX:RVX - Post Discussion

View:
Post by geric on Nov 30, 2021 8:38pm

Merck

F.D.A. panel endorses Merck's Covid pill molnupiravir.  And what has our team been doing since Oct 12?  Apparently can't even find ONE patient to dose.
Comment by priceless on Dec 01, 2021 9:32am
most likely waitiing on financing from either Morroco, or the supreme council  Arab  African economy to kick in a few milllion dollars to look like the hero to solve Covid  in that area of the world. Its crazy how amateur RVX  management is not not convince one BP to collaborate a partnership deal on the COvid trail, Its a travesty imo.   But we have Eversana to save ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities